Recapping Our Top Trades & Stories in Biotech
Recap - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset … Continue Reading
Read nowAuthor Archives: Editorial Staff
Salix and Cosmo: The Merger is Off
Insights - Salix Pharmaceuticals Ltd. (SLXP) announced the end of a $2.7 billion merger agreement with Cosmo Pharmaceuticals SpA (COPN), citing tougher U.S rules for overseas inversions. … Continue Reading
Read now
Esperion One-Ups Rival Cholesterol Drug in Midstage Study
Insights - Esperion Therapeutics Inc (ESPR) hit a home run with top-line results from ETC-1002-008, a 12-week Phase 2b study that is one of the largest ever … Continue Reading
Read now
First Ebola Case in U.S. Keeps the Ebola Trade Rolling
Insights - Just after the close on Tuesday the United States’ Centers for Disease Control and Prevention (CDC) confirmed the first infection of Ebola Zaire in a … Continue Reading
Read now
J&J Puts Up $2 Billion for Viral Therapeutics, Spotlights Two Other Public Companies
Insights - Johnson & Johnson (JNJ) is shelling out $1.75 billion to acquire Alios Biopharma, a private developer of therapeutics for viral diseases. Alios’ lead drug asset is compound … Continue Reading
Read now
Firdapse, Catalyst Pharma Produce Phase 3 Success
Insights - Catalyst Pharmaceuticals’ (CPRX) Firdapse (amifampridine phosphate) hit both co-primary endpoints successfully in a phase 3 trial in Lamberton-Eaton myasthenic syndroms (LEMS), announced on Monday afternoon. The stock climbed 20% … Continue Reading
Read nowThe Liver is Hot in Biotech. All Eyes on November
Recap - November is approaching, and the AASLD’s Liver Meeting conference the second week of the month, attracting a bevy of investors this year. The liver has become … Continue Reading
Read now